MAFFUID PAUL W 4
4 · MABVAX THERAPEUTICS HOLDINGS, INC. · Filed Jan 16, 2018
Insider Transaction Report
Form 4
Transactions
- Sale
Common Stock
2018-01-10$0.96/sh−60,478$58,059→ 367,130 total - Sale
Common Stock
2018-01-11$0.98/sh−35,166$34,463→ 331,964 total - Exercise/Conversion
Common Stock
2018-01-08+406,382→ 427,608 total - Sale
Common Stock
2018-01-12$0.96/sh−10,207$9,799→ 321,757 total - Exercise/Conversion
Restricted Stock Unit
2018-01-08−406,382→ 0 total→ Common Stock (406,382 underlying)
Footnotes (7)
- [F1]Represents conversion of restricted stock units into common stock upon vesting of such units granted on September 15, 2017 and October 2, 2017.
- [F2]Represents a portion of the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs listed in Table II of the reporting person. This sale is mandated by the Issuer's election under the equity incentive plan to require satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
- [F3]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.87 to $1.02 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.95 to $1.02 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.95 to $1.00 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]Each restricted stock unit is the economic equivalent of one share of common stock of the Issuer.
- [F7]Restricted Stock Units vested on January 8, 2018, subject to the Reporting Person's continued employment or service with the Issuer on each such vesting date.